These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9465089)

  • 1. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies.
    Junghans RP; Carrasquillo JA; Waldmann TA
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1752-7. PubMed ID: 9465089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.
    Junghans RP; Waldmann TA
    J Exp Med; 1996 Apr; 183(4):1587-602. PubMed ID: 8666917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement and biological correlates of antibody bioactivity during antibody immunotherapies.
    Hagg DS; Junghans RP
    J Immunol Methods; 1998 Oct; 219(1-2):7-21. PubMed ID: 9831385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.
    Kingsbury GA; Waldmann TA; Junghans RP
    Leukemia; 1998 Jun; 12(6):982-91. PubMed ID: 9639430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.
    Junghans RP; Waldmann TA; Landolfi NF; Avdalovic NM; Schneider WP; Queen C
    Cancer Res; 1990 Mar; 50(5):1495-502. PubMed ID: 2406013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy.
    Waldmann TA
    Cancer Surv; 1989; 8(4):891-903. PubMed ID: 2701734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity.
    Jacques Y; Le Mauff B; Boeffard F; Godard A; Soulillou JP
    J Immunol; 1987 Oct; 139(7):2308-16. PubMed ID: 2821110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
    Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
    Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
    Brown PS; Parenteau GL; Dirbas FM; Garsia RJ; Goldman CK; Bukowski MA; Junghans RP; Queen C; Hakimi J; Benjamin WR
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2663-7. PubMed ID: 2011577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein.
    Robb RJ; Kutny RM
    J Immunol; 1987 Aug; 139(3):855-62. PubMed ID: 3036946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.
    Kozak RW; Atcher RW; Gansow OA; Friedman AM; Hines JJ; Waldmann TA
    Proc Natl Acad Sci U S A; 1986 Jan; 83(2):474-8. PubMed ID: 3079913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A humanized antibody that binds to the interleukin 2 receptor.
    Queen C; Schneider WP; Selick HE; Payne PW; Landolfi NF; Duncan JF; Avdalovic NM; Levitt M; Junghans RP; Waldmann TA
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10029-33. PubMed ID: 2513570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.
    Chaudhary VK; Gallo MG; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9491-4. PubMed ID: 2251289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.
    Depper JM; Leonard WJ; Robb RJ; Waldmann TA; Greene WC
    J Immunol; 1983 Aug; 131(2):690-6. PubMed ID: 6408186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.